Tag Archives: Promising

Promising Breast Cancer Prevention Research: Fewer Side Effects from Raloxifene

June 11, 2012     No comments


(Vocus/PRWEB) December 13, 2010

Results from an ongoing study examining two drugs to prevent breast cancer found that the drug raloxifene (Evista) was as almost effective as the standard drug tamoxifen (Nolvadex) and also produced fewer side effects. Earlier results of the study had shown that raloxifene was as effective as tamoxifen in reducing non-invasive breast cancer in post-menopausal women at high risk of developing the disease. For both drugs, women experienced a 50 percent reduction in breast cancer risk after 4 years. These latest results show that tamoxifen continues to reduce risk for both invasive and non-invasive breast cancer by about 50 percent after 5 years of drug use, and raloxifene reduces risk for invasive and non-invasive breast cancer by about 38 percent.

The National Surgical Adjuvant Breast and Bowel Project (NSABP) is leading the STAR clinical trial?one of the largest trials of on breast cancer prevention ever undertaken. STAR, or Study of Tamoxifen and Raloxifene, is investigating whether the drugs tamoxifen (brand name, Nolvadex) and raloxifene (Evista), help prevent breast cancer in women at high risk for disease. Both tamoxifen and raloxifene are “anti-estrogens.” Anti-estrogens work by competing with estrogen to bind to estrogen receptors in breast cancer cells. By blocking estrogen in the breast, tamoxifen and raloxifene may slow the growth and reproduction of breast cancer cells

In April 2006, researchers announced the initial results of STAR, which showed that raloxifene may be as effective as tamoxifen at preventing breast cancer in women at high risk for the disease. Specifically, those results showed that women who were given raloxifene reduced their risk of breast cancer by 50%. In addition, raloxifene may have fewer potentially serious side effects than tamoxifen. After an average of four years on raloxifene, women in the study developed about 36% fewer uterine cancers and 29% fewer blood clots than the women who took tamoxifen.

These latest results show that raloxifene is nearly as effective at preventing invasive breast cancer in high-risk women and produces fewer side effects. Specifically, the results show that after taking the drug for 5 years then stopping, raloxifene retained 76% of the effectiveness of tamoxifen in preventing invasive disease and grew closer to tamoxifen in preventing noninvasive disease while producing fewer side effects such as bone fractures, blood clots, or cataracts.

Tamoxifen has been shown to reduce the incidence of noninvasive breast cancers:

?specifically lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS)

?by 50%. The latest study results show that raloxifene reduces the risk of non-invasive breast cancer by about 38 percent compared to tamoxifen?s 50% reduction rate.

When deciding between tamoxifen and raloxifene, the National Cancer Institute advises the following: Postmenopausal women who are at increased risk of breast cancer should consider taking either raloxifene or tamoxifen to reduce their risk. As with any medical procedure or intervention, the decision to take one of these drugs is an individual one in which the benefits and risks of therapy must be considered. The balance of these benefits and risks will vary depending on a woman’s personal health history and how she weighs the benefits and risks. Even if a woman is at increased risk of breast cancer, raloxifene or tamoxifen therapy may not be right for her. Women who are considering breast cancer prevention therapy should talk with their health care provider.

Additional Resources and References:

-The National Surgical Adjuvant Breast and Bowel Project, http://www.nsabp.pitt.edu/

-The National Cancer Institute, http://www.cancer.gov/

###





Find More Carcinoma Press Releases

Read More

Increasing Investment in Stem Cell Technology and Promising Research Outcomes Drives the Stem Cell Research Market, According to New Report by Global Industry Analysts

May 12, 2012     No comments

San Jose, California (PRWEB) May 10, 2012

Follow us on LinkedIn ? Stem cell research is a promising area of biotechnology, which holds tremendous potential in rendering a new approach to the treatment of various degenerative diseases. The area deals with employing regenerative stem cells for the replenishment of damaged cells of a particular organ or tissue with new cells. These repair blocks have created a new specialty in the area of medicine called the regenerative medicine. Stem cells hold potential to treat conditions such as Alzheimer?s disease, Parkinson?s disease, stroke, spinal cord injury, heart disease, diabetes, burns, rheumatoid arthritis and osteoarthritis. In addition to its therapeutic applications, stem cells are also finding use in drug discovery, promising new avenues in the area of drug development. Growth in the research space is attributed to the acceptance of stem cell technology by patients for treating chronic diseases. Moreover advancement in stem cell research can help reduce the escalating healthcare costs associated with conventional methods of treatment.

Stem cell technology is still in a nascent stage. The market still lacks substantial data that could establish its long-term efficacy as well as safety. Certain issues pertaining to its administration have also raised concerns. The regulatory and ethical barriers across the world, particularly in Western countries, are the major challenges ahead of stem cells research. The barriers are particularly more in embryonic stem cell research. On the other hand, countries such as India, with comparatively less opposition, are better positioned to conduct stem cell research. Lack of proper funding is also a matter of concern for stem cell research. Countries, such as Thailand, Taiwan, Malaysia, Singapore, China, and India, are engaged in commercial, clinical, and scientific advancements in stem cell research without proper funding.

Over the past few years, the stem cells market has witnessed several breakthroughs that bodes tremendous potential in reshaping the area of medicine. Potential therapeutic applications of stem cells cut across several debilitating and deadly disease areas, including cancer and AIDS. Stem cell research is entering new avenues of medicine, and promises to provide a solution to combat diseases that were hitherto believed to be incurable. There is a growing demand for such therapies, which in turn provokes continued investments in the area, and foretell a remarkable growth in the industry in the coming years. Presently, the field is focused upon the treatment of certain oncological ailments, which include non-Hodgkin’s lymphoma, multiple myeloma, and leukaemia. Additionally, non-cancerous diseases, including lupus, immunodeficiency, and aplastic anaemia, are also being investigated for treatment using stem cell technology.

Mesenchymal stem cells and hematopoietic stem cells, extracted from adult bone marrow, are the leading types of adult stem cells currently in demand in the area of medicine. Of these types, hematopoietic stem cells hold major share in disease management. The dominance of hematopoietic stem cells is in part due to the difficulty associated with the isolation of mesenchymal from the bone marrow owing to availability of cells in lower levels. The greatest strength of adult stem cells is the presence of genomic stability of a very high degree. Additionally, stem cell therapy does not necessitate pre-treatment or genetic modification that is required when dealing with embryonic stem cells.

The US represents the largest regional market worldwide, as stated by the new market research report on Stem Cell Research. Despite the 9-year ban, which ended in 2009, over federal funding for research in embryonic stem cells, North America is presently dominating the stem cell market. Key factors that have kept North American market on the top of the charts include advanced stem cell research infrastructure and facilities, and federal support for the research. Asia is emerging as the fastest growing regional market for stem cell research worldwide with countries such as Japan, China, Singapore, Korea, and Australia evolving as major hubs for stem cell research.

Major players profiled in the report include Advanced Cell Technology Inc., Athersys Inc., Cytori Therapeutics Inc., Genzyme Corporation, Geron Corporation, International Stem Cell Corporation, Mesoblast Ltd., Osiris Therapeutics Inc., StemCells Inc., ThermoGenesis Corp., among others.

The research report titled ?Stem Cell Research: A Global Strategic Business Report? announced by Global Industry Analysts, Inc., provides comprehensive market overview, trends & issues, regulatory overview, overview on therapies under development, recent industry activity and profiles of market players worldwide. The report analyzes global adult stem cell research market in terms of annual investments in value for the years 2008 through 2017, for major geographic markets, including the US, Europe and Rest of World.

For more details about this comprehensive market research report, please visit ?

http://www.strategyr.com/Stem_Cell_Research_Market_Report.asp

About Global Industry Analysts, Inc.

Global Industry Analysts, Inc., (GIA) is a leading publisher of off-the-shelf market research. Founded in 1987, the company currently employs over 800 people worldwide. Annually, GIA publishes more than 1300 full-scale research reports and analyzes 40,000+ market and technology trends while monitoring more than 126,000 Companies worldwide. Serving over 9500 clients in 27 countries, GIA is recognized today, as one of the world’s largest and reputed market research firms.

Follow us on LinkedIn

Global Industry Analysts, Inc.

Telephone: 408-528-9966

Fax: 408-528-9977

Email: press(at)StrategyR(dot)com

Web Site: http://www.StrategyR.com/

###







Read More

Anti-oxidant Therapy Presents a Promising Strategy in Prevention or Delaying the Onset and Progression of Alzheimer

April 12, 2012     No comments

Miami, FL (PRWEB) February 26, 2012

A newly published study suggests two strategies to prevent or delay the progression of Alzheimer, more specifically, an early antioxidant intervention and improving the functions of the neurotransmitters acetylcholine. While agreeing with the early anti-oxidant intervention, Nutri-Med Logic Corp adds that a competent body of research has shown a direct link between Cholinergic System (Acetylcholine) and inflammation. Accordingly, an early anti-inflammatory diet would offer an added benefit, in early Alzheimer?s.

According to this study, in animal models, the recording (spatial) memory impairment was accompanied by significant decrease in neurotransmitter acetylcholine, as well as a decline in the anti-oxidant defense. Thus, suggesting oxidative damage and acetylcholine dysfunctions in early Alzheimer models.

A fairly recent but notable study by the School of Health Science and Healthcare Administration of University of Atlanta, also proposes that lack of methyl groups (a group of nutrients) together with oxidative stressors appears to be a central initiating factor for vascular abnormalities for most Alzheimer disease. (1)

Studies in the role of oxidative damage and Alzheimer patients dates back to 1980?s. Oxidative damage manifests a redox (reduction-oxidation) imbalance. According to The Department of Internal Medicine of University of Miami, the cellular redox is regulated by three systems, two of which are also regulated by glutathione. (2)

This recent study also implicates a decrease in superoxide dismutase (SOD), and glutathione peroxidase, two anti-oxidant systems that protect the cells from oxidative damage, in early Alzheimer models.

R-Alpha Lipoic, a nutrient and a potent internal anti-oxidant, has conclusively shown its ability to increase the glutathione levels in the human body.

Additionally, according to this recent study, improving cholinergic (acetylcholine) dysfunction is the other proposed target in delaying the onset and the progression of Alzheimer?s.

Pathogenesis of Alzheimer?s disease has been directly associated with a deficiency in the brain neurotransmitter acetylcholine.

In the brain, there is continuous conversion from choline (a nutrient) to acetylcholine and, again, back to choline. Agents (inhibitors) that do not permit reconversion of acetylcholine back to choline have been used for the symptomatic treatment of Alzheimer?s patients.

A growing body of evidence suggests the definitive role for acetylcholine in suppression of cytokine (inflammatory agents) release through a ?cholinergic anti-inflammatory pathway?

In the normal physiological processes, the human brain and the nervous system resolve inflammation through Resolvin (resolution-phase interaction products) D, a derivative of DHA omega-3 fatty acids, which can only be attained through diet or dietary supplementation.

Lack of DHA Omega-3 fatty acids increases the need for alternative resolution of inflammation, including but not limited to acetylcholine.

In conclusion, Nutri-Med Logic Corp agrees with this study and the early anti-oxidant intervention in Alzheimer?s. Nutri-Med Logic Corp adds that due to the established link between acetylcholine and inflammation, addition of an early anti-inflammatory diet would as important as the anti-oxidant diet.

Nutri-Med Logic Corp is the producer of an effective anti-inflammatory nutrient: The Natural, Deodorized and Concentrated Omega-3, which is also a Pharmaceutical Grade Omega-3;

Nutri-Med Logic Corp is also a producer of dietary supplements such as a Pharmaceutical Grade R-Alpha Lipoic Acid, a potent anti-oxidant and the dietary supplement of choice for the Diabetics, in Germany for decades;

Producer of PolyEnylPhosphatidylCholine (PPC 425mg), an extract of soy, a pure and effective dietary source of choline and the recommended dietary supplement for those with Fatty Liver and Alcoholic Liver Disease, in Europe for decades.

Nutri-Med Logic Corp invites you to visit its News Archives and Review other News Releases on R-Alpha Lipoic and anti-inflammatory nutrients such as Omega-3 and What Is Omega-3 Good For.

Nutri-Med Logic’s products are Formulated Based on Nutritional Logic, made from the highest quality raw materials that are manufactured in pharmaceutical facilities, encapsulated in pharmaceutical facilities and packaged in pharmaceutical facilities.

It must be noted that the studies, sources or statements above and below have not been evaluated by The FDA and, thus, one should not relate the cause of any diseases, stated herein, to lack of the dietary supplements, stated herein, nor equate their supplementation to prevention, treatment or cure.

1. Recent Pat Cardiovasc Drug Discov. 2011 Sep;6(3):222-41

2. Drugs. 2011 Jul 30;71(11):1385-96

###





Read More
Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv